|
| [ На главную ] -- [ Список участников ] -- [ Правила форума ] -- [ Зарегистрироваться ] |
| On-line: |
| Клуб болельщиков "Торпедо" Владимир / / mUZYXZyxaOPvzy |
| Страницы: 1 |
|
| Автор | Сообщение |
|
Julio Гость |
Добавлено: 30-06-2022 08:55 |
|
How much notice do you have to give? ciprofloxacino suspension The topline data on ALN-TTRsc come from an ongoing Phase I study in the U.K. involving 40 healthy volunteers, with full results expected during the annual Heart Failure Society of America meeting in September in Orlando, FL. It closely follows Alnylam's ALN-TTR02, its most advanced therapy for TTR-mediated amyloidosis (ATTR), which is being developed for patients with familial amyloidotic polyneuropathy (FAP). |
| Страницы: 1 |
|
| Клуб болельщиков "Торпедо" Владимир / / mUZYXZyxaOPvzy |